Royalty Pharma plc (RPRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN USG7709Q1043
Royalty Pharma plc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.38 bn USD |
| Operating income | 1.56 bn USD |
| EBIT | 1.63 bn USD |
| Net income | 770.95 m USD |
| Diluted EPS – continuing operations | 1.78 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
More stocks
- COSCO SHIPPING Holdings Co Ltd (601919.SS)
- WEC Energy Group (WEC)
- ABN Amro Bank NV (ABN.AS)
- Okta, Inc. (OKTA)
- Ubiquiti Inc. (UI)
- Powszechna Kasa Oszczednosci Bank Polski SA (PKO.WA)
- Sumitomo Electric Industries Ltd (5802.T)
- Repsol SA (REP.MC)
- Dassault Systemes SE (DSY.PA)
- Sika AG (SIKA.SW)
- JD.com Inc (9618.HK)
- CTBC Financial Holding Co. Ltd. Pfd. (2891C.TW)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.